Meropol NJ - Search Results

1

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.

Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Sasson AR, et al. Among authors: meropol nj. Int J Gastrointest Cancer. 2003;34(2-3):121-8. doi: 10.1385/IJGC:34:2-3:121. Int J Gastrointest Cancer. 2003. PMID: 15361645

2

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.

von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM. von Mehren M, et al. Clin Cancer Res. 2000 Jun;6(6):2219-28. Clin Cancer Res. 2000. PMID: 10873071 Clinical Trial.

3

Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas.

Arnoletti JP, Hoffman JP, Ross EA, Kagan SA, Meropol NJ, Freedman G, Eisenberg B. Arnoletti JP, et al. Among authors: meropol nj. Am Surg. 2002 Apr;68(4):330-5; discussion 335-6. Am Surg. 2002. PMID: 11952242

4

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Cohen SJ, et al. Among authors: meropol nj. J Clin Oncol. 2003 Apr 1;21(7):1301-6. doi: 10.1200/JCO.2003.08.040. J Clin Oncol. 2003. PMID: 12663718 Clinical Trial.

5

Drug development in pancreatic cancer: finally, biology begets therapy.

Cohen SJ, Meropol NJ. Cohen SJ, et al. Among authors: meropol nj. Int J Gastrointest Cancer. 2002;32(2-3):91-106. doi: 10.1385/IJGC:32:2-3:91. Int J Gastrointest Cancer. 2002. PMID: 12794245 Review.

6

Development of new agents for the treatment of advanced colorectal cancer.

Lewis NL, Meropol NJ. Lewis NL, et al. Among authors: meropol nj. Clin Colorectal Cancer. 2003 Nov;3(3):154-64. doi: 10.3816/CCC.2003.n.021. Clin Colorectal Cancer. 2003. PMID: 14706174 Review.

7

Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer.

Subhi AL, Tang B, Balsara BR, Altomare DA, Testa JR, Cooper HS, Hoffman JP, Meropol NJ, Kruger WD. Subhi AL, et al. Among authors: meropol nj. Clin Cancer Res. 2004 Nov 1;10(21):7290-6. doi: 10.1158/1078-0432.CCR-04-0972. Clin Cancer Res. 2004. PMID: 15534104

8

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. Carlini LE, et al. Among authors: meropol nj. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. Clin Cancer Res. 2005. PMID: 15709193 Clinical Trial.

9

Changing patterns of bone and brain metastases in patients with colorectal cancer.

Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Sundermeyer ML, et al. Among authors: meropol nj. Clin Colorectal Cancer. 2005 Jul;5(2):108-13. doi: 10.3816/ccc.2005.n.022. Clin Colorectal Cancer. 2005. PMID: 16098251

10

Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience.

Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD, Cohen SJ, Watson JC, Eisenberg D, McGarrity E, Freedman G, Meropol NJ. Konski A, et al. Among authors: meropol nj. Semin Oncol. 2005 Dec;32(6 Suppl 9):S63-7. doi: 10.1053/j.seminoncol.2005.04.026. Semin Oncol. 2005. PMID: 16399435

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

294 results

Search Page

Filters